Galapagos and Prolysis extend research collaboration

03-Jan-2006

Galapagos NV and Prolysis Ltd announced an extension of the research collaboration started in 2005. BioFocus, the service division of Galapagos, is progressing a lead optimisation program for Prolysis to identify dual enzyme inhibitors that can overcome the problem of antibiotic resistance. Under the terms of the collaboration, Prolysis will fund BioFocus research for medicinal chemistry work throughout 2006. Prolysis also has the option to access in vitro ADMET and computational chemistry services from BioFocus during that period.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance